Shionogi & Co., Ltd. (SGIOY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Shionogi & Co., Ltd. (SGIOY) Healthcare & Pipeline Overview

Shionogi & Co., Ltd., a Japanese pharmaceutical company established in 1878, specializes in developing and distributing pharmaceuticals, diagnostic reagents, and medical devices, with a focus on infectious diseases and central nervous system disorders, competing within the global specialty and generic drug market and demonstrating a strong profit margin of 41.9%.

What Is the Investment Thesis for SGIOY?

Shionogi & Co., Ltd. presents a compelling investment case based on its focus on innovative pharmaceuticals and strong profitability, indicated by a 41.9% profit margin. Key value drivers include the continued success of its flagship products like Fetroja and Xofluza, along with the potential of its extensive drug pipeline targeting various therapeutic areas. Upcoming catalysts include the advancement of drugs like Zuranolone for depression and S-723595 for NASH through clinical trials. However, investors should be aware of risks associated with pharmaceutical development, such as clinical trial failures and regulatory hurdles. The company's P/E ratio of 11.4 suggests a reasonable valuation relative to its earnings.

Based on FMP financials and quantitative analysis

SGIOY Key Highlights

• Market capitalization of $15.0B reflects Shionogi's significant presence in the pharmaceutical industry.
• Profit margin of 41.9% demonstrates strong profitability and efficient operations.
• Gross margin of 84.3% indicates effective cost management in pharmaceutical production.
• Dividend yield of 1.79% provides a steady income stream for investors.
• Beta of 0.02 suggests low volatility compared to the overall market.

Who Are SGIOY's Competitors?

SGIOY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SGIOY's Key Strengths?

• Strong pipeline of drugs in development.
• Established presence in the Japanese pharmaceutical market.
• High profit margin and gross margin.
• Expertise in infectious disease treatments.

What Are SGIOY's Weaknesses?

• Reliance on a limited number of key products.
• Geographic concentration in Japan.
• Exposure to patent expiration risks.
• Dependence on partnerships for certain drug development programs.

What Could Drive SGIOY Stock Higher?

• Clinical trial results for Zuranolone in depression expected in Q4 2026.
• Regulatory approval decisions for S-723595 in NASH anticipated in 2027.
• Continued revenue growth from key products like Fetroja and Xofluza.
• Expansion of strategic collaborations and partnerships.
• Progress in the development of COVID-19 treatments.

What Are the Key Risks for SGIOY?

• Failure of clinical trials for key drug candidates.
• Regulatory delays or rejection of drug approvals.
• Increasing competition from generic drug manufacturers.
• Patent expiration risks for key products.
• Product liability claims and litigation.

What Are the Growth Opportunities for SGIOY?

• Expansion of Infectious Disease Portfolio: Shionogi has a significant opportunity to expand its infectious disease portfolio, particularly with its existing drugs like Fetroja and Xofluza. The global market for infectious disease treatments is projected to reach $250 billion by 2028, driven by increasing antibiotic resistance and emerging infectious diseases. Shionogi's ongoing research and development efforts in this area could lead to the introduction of new and innovative treatments, capturing a larger share of this growing market.
• Development of Central Nervous System (CNS) Therapies: Shionogi is actively developing therapies for CNS disorders, including depression and neuropathic pain. The CNS therapeutics market is expected to reach $150 billion by 2027, fueled by the increasing prevalence of mental health disorders and neurological conditions. Successful development and commercialization of drugs like Zuranolone could significantly contribute to Shionogi's revenue growth.
• Advancement of NASH Treatment: Shionogi's development of S-723595 for NASH (nonalcoholic steatohepatitis) represents a significant growth opportunity. The NASH market is projected to reach $35 billion by 2030, driven by the rising prevalence of obesity and diabetes. If S-723595 proves to be an effective treatment, Shionogi could become a major player in this rapidly expanding market.
• Strategic Collaborations and Partnerships: Shionogi's existing collaborations with Nagasaki University and other institutions provide a platform for developing new antimalarial drugs and other innovative therapies. By forming strategic partnerships with research institutions and other pharmaceutical companies, Shionogi can leverage external expertise and resources to accelerate its drug development pipeline and expand its market reach.
• Geographic Expansion: While Shionogi primarily operates in Japan, there is a significant opportunity to expand its geographic presence, particularly in North America and Europe. By obtaining regulatory approvals for its key products in these regions and establishing distribution networks, Shionogi can tap into larger markets and diversify its revenue streams. This expansion could be achieved through partnerships or direct investment in overseas operations.

What Opportunities Does SGIOY Have?

• Expansion into new therapeutic areas.
• Geographic expansion into North America and Europe.
• Strategic acquisitions of complementary businesses.
• Development of innovative drug delivery systems.

What Threats Does SGIOY Face?

• Increasing competition from generic drug manufacturers.
• Stringent regulatory requirements and approval processes.
• Patent litigation and intellectual property disputes.
• Economic downturns and healthcare spending cuts.

What Are SGIOY's Competitive Advantages?

• Strong research and development capabilities.
• Proprietary drug formulations and patents.
• Established distribution network in Japan.
• Expertise in infectious disease treatments.

What Does SGIOY Do?

Shionogi & Co., Ltd., founded in 1878 as Shionogi Shoten Co., Ltd. and renamed in 1943, is a Japanese pharmaceutical company headquartered in Osaka. The company is dedicated to the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Shionogi's product portfolio includes treatments for infectious diseases, pain management, and central nervous system disorders. Key products include Fetroja, a treatment for multidrug-resistant gram-negative bacterial infections; Xofluza, an influenza virus drug; and Tivicay, used in HIV treatment. The company also develops treatments for opioid-induced constipation (Symproic) and has a pipeline of drugs targeting inflammatory pain, neuropathic pain, insomnia, and obesity. Shionogi has collaboration agreements with institutions like Nagasaki University to develop antimalarial drugs. The company operates primarily in Japan, with a global presence through its innovative pharmaceutical products.

What Products and Services Does SGIOY Offer?

• Researches and develops pharmaceutical products.
• Manufactures pharmaceutical drugs and diagnostic reagents.
• Distributes pharmaceuticals and medical devices.
• Focuses on treatments for infectious diseases.
• Develops therapies for pain management.
• Creates drugs for central nervous system disorders.
• Offers diagnostic test kits for COVID-19.

How Does SGIOY Make Money?

• Develops and patents innovative pharmaceutical products.
• Generates revenue through the sale of prescription drugs.
• Partners with research institutions to discover new drug candidates.
• Commercializes and distributes its products globally.

What Industry Does SGIOY Operate In?

Shionogi & Co., Ltd. operates within the global pharmaceutical industry, which is characterized by intense competition, stringent regulatory requirements, and high research and development costs. The industry is driven by innovation, with companies constantly seeking to develop new and improved treatments for various diseases. Shionogi's focus on specialty and generic drugs positions it within a segment that is experiencing growth due to aging populations and increasing healthcare needs. Competitors include companies like ALBHF, BIOVF, BMXMF, CHJTF, and CSPCY, all vying for market share in various therapeutic areas.

Who Are SGIOY's Key Customers?

• Hospitals and clinics.
• Pharmacies and drug stores.
• Healthcare providers.
• Patients requiring prescription medications.

FY2026 estForward Outlook

Wall Street analysts project Shionogi & Co., Ltd. revenue of about $509.31B for fiscal 2026, with EPS near $116.96. The estimate reflects 6 contributing analysts.

SGIOY Valuation & Market Position

With a $15.0B market cap, Shionogi & Co., Ltd. sits in the large-cap segment of the market. Relative to its peer group, SGIOY's quantitative score of 61/100 is above the peer average of 50/100.

ROE 14%Key Financial Metrics

Return on equity for Shionogi & Co., Ltd. stands at 13.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.0%, showing how much profit it generates from its asset base. SGIOY trades at a trailing price-to-earnings ratio of 11.43, below the Healthcare sector average of ~23x. Its free cash flow yield is 8.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.58 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 8.5%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Shionogi & Co., Ltd.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.14 places it in the safe zone, indicating low near-term bankruptcy risk.

Company Profile

Shionogi & Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Osaka, JP. The company is led by CEO Isao Teshirogi. SGIOY has traded publicly since 2015.

SGIOY Financials

SGIOY Latest News

SGIOY Analyst Consensus

SGIOY MoonshotScore

What Investors Ask About Shionogi & Co., Ltd. (SGIOY) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources